Experts are expecting this Memorial Day weekend to be the busiest yet, with nearly 44 million Americans projected to travel ...

drug in agitation associated with schizophrenia and bipolar disorder, and has a phase 3 programme running in Alzheimer’s patients. Axsome, meanwhile, recently reported positive results in its ...

Nootropics are touted as “smart drugs” meant to improve cognitive performance. But there’s a lot we still don’t know about ...

Firms developing Alzheimer’s drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be ...

Are you worried, restless, or having trouble concentrating most of the time? It could be anxiety. This common mental health ...

First Successful Clinical Trial of VU319 Brings Alzheimer's Treatment One Step Closer Dec. 19, 2024 — Phase I clinical trial of a drug was successfully ... route or the best way to navigate ...

(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc.

Groundbreaking research reveals potential link between cytomegalovirus (CMV) and Alzheimer's disease, offering new insights ...

IGC Pharma, Inc, an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer’s disease and transforming patient care with fast-acting, safe, and ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc. and Eli ...

Alzheimer’s treatments are a potential $13 billion market by 2030, with major pharma cos investing heavily. Biogen and Eli Lilly have drugs like Leqembi and Kisunla available, but challenges remain.

The supplement's two main ingredients, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), help promote healthy blood ...